Sigma Healthcare's proposed merger with Chemist Warehouse Group gains ACCC approval

HMC Capital Partners Fund I (HMCCP of the Fund) as a major shareholder in Sigma Healthcare (Sigma) is pleased to share the ACCC’s decision to not oppose the proposed merger between Sigma and Chemist Warehouse Group.

A review process by the ACCC concluded the merger was unlikely to substantially lessen competition in the pharmacy supply chain. The merger process will now progress to seek both Sigma and Chemist Warehouse Group shareholder approvals, with completion likely to occur during the first half of CY2025.

HMCCP’s significant interest in Sigma was the seed asset for the Fund at inception in August 2022. Since then, HMCCP has been a highly active and supportive shareholder which included helping Sigma to structure and negotiate the proposed merger with Chemist Warehouse Group that was announced in December 2023. 

The proposed merger is transformational for Sigma, creating a leading healthcare wholesaler, distributor and retail pharmacy franchisor with an implied market capitalisation post completion in excess of $25bn. 

For further information contact invest@hmccapital.com.au or read the statement in full here.

Disclaimer
Past performance should not be taken as an indicator of future performance.  This general information does not take into account your investment objectives, financial situation or needs.  See https://www.hmccapital.com.au/investment-strategies/private-equity/hmc-capital-partners-fund-i/ for more information on HMC Capital Partners Fund I.